12 Month Price Forecast For NTRA
Distance to NTRA Price Forecasts
NTRA Price Momentum
🤔 Considering Natera (NTRA)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: January 23, 2025 11:19 AM UTC
NTRA Analyst Ratings & Price Targets
Based on our analysis of 23 Wall Street analysts, NTRA has a consensus that is bullish. The median price target is $183.00, with forecasts ranging from $37.00 to $210.00. Currently, there are 17 Buy ratings, 0 Hold ratings, and 1 Sell ratings.
With NTRA currently trading at $171.93, the median price forecast suggests a 6.4% upside. The most optimistic forecast comes from at , projecting a 22.1% upside, while at provides the most conservative target, suggesting a -78.5% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
NTRA Analyst Consensus
NTRA Price Target Range
Latest NTRA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for NTRA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jan 17, 2025 | Guggenheim | Subbu Nambi | Buy | Maintains | $200.00 |
| Jan 10, 2025 | Bernstein | Eve Burstein | Outperform | Maintains | $200.00 |
| Jan 3, 2025 | Canaccord Genuity | Kyle Mikson | Buy | Maintains | $180.00 |
| Dec 13, 2024 | JP Morgan | Julia Qin | Overweight | Maintains | $200.00 |
| Nov 18, 2024 | Piper Sandler | David Westenberg | Overweight | Maintains | $200.00 |
| Nov 14, 2024 | Morgan Stanley | Tejas Savant | Overweight | Maintains | $176.00 |
| Nov 13, 2024 | TD Cowen | Dan Brennan | Buy | Maintains | $175.00 |
| Nov 13, 2024 | JP Morgan | Julia Qin | Overweight | Maintains | $160.00 |
| Nov 13, 2024 | Canaccord Genuity | Kyle Mikson | Buy | Maintains | $165.00 |
| Nov 13, 2024 | Craig-Hallum | Alexander Nowak | Buy | Maintains | $157.00 |
| Nov 13, 2024 | Baird | Catherine Ramsey | Outperform | Maintains | $160.00 |
| Oct 30, 2024 | Bernstein | Eve Burstein | Outperform | Maintains | $135.00 |
| Oct 29, 2024 | Canaccord Genuity | Kyle Mikson | Buy | Maintains | $150.00 |
| Oct 17, 2024 | Leerink Partners | Puneet Souda | Outperform | Maintains | $150.00 |
| Oct 16, 2024 | Goldman Sachs | Matthew Sykes | Buy | Maintains | $140.00 |
| Sep 13, 2024 | Piper Sandler | David Westenberg | Overweight | Reiterates | $150.00 |
| Aug 27, 2024 | Canaccord Genuity | Kyle Mikson | Buy | Maintains | $145.00 |
| Aug 13, 2024 | Morgan Stanley | Tejas Savant | Overweight | Maintains | $132.00 |
| Aug 13, 2024 | Piper Sandler | David Westenberg | Overweight | Maintains | $150.00 |
| Aug 9, 2024 | BTIG | Mark Massaro | Buy | Maintains | $135.00 |
Stocks Similar to Natera Inc
The following stocks are similar to Natera based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Natera Inc (NTRA) Financial Data
Natera Inc has a market capitalization of $22.11B with a P/E ratio of -45.5x. The company generates $1.53B in trailing twelve-month revenue with a -14.0% profit margin.
Revenue growth is +63.9% quarter-over-quarter, while maintaining an operating margin of -8.9% and return on equity of -25.8%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Natera Inc (NTRA) Company Overview
About Natera Inc
Develops and commercializes molecular testing services.
The company generates revenue by offering a variety of molecular testing services, including non-invasive prenatal tests, genetic screening, and cancer detection tests. These services are marketed directly to consumers and healthcare providers, as well as through partnerships with laboratories and distributors, which helps to expand its reach in the diagnostics market.
Founded in 2003 and headquartered in Austin, Texas, Natera has established partnerships to enhance its testing capabilities and expand its product offerings. Its diverse range of tests addresses various medical needs, from prenatal care to cancer monitoring, positioning the company well within the growing personalized medicine and genomics sectors.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
3,282
CEO
Mr. Steven Leonard Chapman
Country
United States
IPO Year
2015
Website
www.natera.comNatera Inc (NTRA) Latest News & Analysis
Natera, Inc. (NASDAQ: NTRA) will present new data from the BESPOKE CRC study at the ASCO GI Symposium on Jan. 25, 2025, in San Francisco.
Natera's upcoming data presentation at ASCO GI could signal advancements in genetic testing, potentially boosting its market position and influencing stock performance.
Natera, Inc. CEO Steve Chapman has been recognized as a top healthcare technology CEO for 2024 and named "BioTechnology Innovator of the Year" at the BioTech Breakthrough Awards.
Recognition of Natera's CEO underscores strong leadership and innovation, potentially boosting investor confidence and positioning the company favorably in the competitive biotech market.
Natera, Inc. (NASDAQ: NTRA) will update investors at the J.P. Morgan Healthcare Conference, discussing its 2024 financial results and innovation plans for oncology.
Natera's update on strong preliminary financial results and its innovation roadmap could signal growth potential, impacting stock performance and investor sentiment in the healthcare sector.
Natera, Inc. (NASDAQ: NTRA) expects Q4 2024 revenues of ~$472M, up 52% from Q4 2023, and full-year 2024 revenues of ~$1.7B.
Natera's projected revenue growth of 52% in Q4 2024 and $1.7 billion for the year signals strong market demand, potentially boosting investor confidence and stock performance.
Investor Stanley Druckenmiller remains active in stock picking through his Duquesne Family Office, continuing his legacy from his time at George Soros' Quantum Group of Funds.
Stanley Druckenmiller's continued activity in stock picking signals confidence in market opportunities, potentially influencing investor sentiment and stock valuations.
Natera, Inc. (NASDAQ: NTRA) will present at the J.P. Morgan Healthcare Conference on Jan. 15, 2025, at 9:00 a.m. PT. A live webcast will be available on its investor relations site.
Natera's participation in a major healthcare conference signals potential updates on its growth and innovations, which can influence stock performance and investor sentiment.
Frequently Asked Questions About NTRA Stock
What is Natera Inc's (NTRA) stock forecast for 2025?
Based on our analysis of 23 Wall Street analysts, Natera Inc (NTRA) has a median price target of $183.00. The highest price target is $210.00 and the lowest is $37.00.
Is NTRA stock a good investment in 2025?
According to current analyst ratings, NTRA has 17 Buy ratings, 0 Hold ratings, and 1 Sell ratings. The stock is currently trading at $171.93. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for NTRA stock?
Wall Street analysts predict NTRA stock could reach $183.00 in the next 12 months. This represents a 6.4% increase from the current price of $171.93. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Natera Inc's business model?
The company generates revenue by offering a variety of molecular testing services, including non-invasive prenatal tests, genetic screening, and cancer detection tests. These services are marketed directly to consumers and healthcare providers, as well as through partnerships with laboratories and distributors, which helps to expand its reach in the diagnostics market.
What is the highest forecasted price for NTRA Natera Inc?
The highest price target for NTRA is $210.00 from at , which represents a 22.1% increase from the current price of $171.93.
What is the lowest forecasted price for NTRA Natera Inc?
The lowest price target for NTRA is $37.00 from at , which represents a -78.5% decrease from the current price of $171.93.
What is the overall NTRA consensus from analysts for Natera Inc?
The overall analyst consensus for NTRA is bullish. Out of 23 Wall Street analysts, 17 rate it as Buy, 0 as Hold, and 1 as Sell, with a median price target of $183.00.
How accurate are NTRA stock price projections?
Stock price projections, including those for Natera Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
